EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Robert F. Apple, EVP, CFO and President of the Parenteral Products Division will present at the BMO 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010 at 8:30 a.m. ET (Eastern Time).
An audio web cast of the presentation will be available under the investor relations section of the Antares website at www.antarespharma.com.
About Antares Pharma
Antares Pharma focuses on self-injection delivery technologies and topical gel-based pharmaceutical products. The Company's subcutaneous and intramuscular injection technology platforms include VIBEXTM disposable pressure-assisted auto injectors, ValeoTM/VisionTM reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd that includes Tev-Tropin(R) human growth hormone and a partnership with Ferring Pharmaceuticals. In the gel-based area, the Company's lead product candidate is Anturol(R) an oxybutynin ATDTM gel for the treatment of OAB (overactive bladder)l. Antares also has a partnership with BioSante that includes LibiGel(R) (transdermal testosterone gel) in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin(R) (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development and product commercialization activities in Minneapolis, Minnesota and Muttenz, Switzerland.
Antares Pharma, Inc.
Robert F. Apple
Chief Financial Officer
Westwicke Partners, LLC
John Woolford, 443-213-0506
Tiberend Strategic Advisors, Inc.
Tamara Bright, 212-827-0020
KEYWORDS: United States North America New Jersey
INDUSTRY KEYWORDS: Health Biotechnology Medical Devices Pharmaceutical